As demonstrated by Kurimchack et al., high endogenous levels of the MDR1 protein resulted in a significant decrease in the efficacy of Cereblon-based PROTAC dBET6 when compared with PROTACs-naïve cancer cells with low expression of MDR1201. This evidence concerns the gene ABCB1 and cancer.